Pharmafile Logo
Pharmafocus logo
Advanced Search

keytruda

Showing 15 posts of 133 posts found.

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024
Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda

Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …

News

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024
Research and Development Gastric, MSD, Merck, Oncology, keytruda

Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …

News

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

April 10, 2024
Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …

News

Merck shares results for Keytruda in cervical cancer treatment

March 18, 2024
Research and Development Merck, Oncology, cervical cancer, keytruda, women's health

Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, …

News

FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment

January 15, 2024
Medical Communications FDA, Oncology, cervical cancer, keytruda

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

News

FDA approves Merck’s Keytruda for gastric cancer treatment

November 17, 2023
Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda

Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …

News

Merck’s Keytruda approved by EC for gastric cancer

August 30, 2023
Research and Development EC, Merck, Oncology, gastric cancer, keytruda

Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …

News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

Merck shares data from phase 3 trial for breast cancer treatment

August 1, 2023
Research and Development MSD, Merck, Oncology, breast cancer, keytruda

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …

News
merck-keytruda

NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

October 22, 2020
Sales and Marketing MSD, NCIE, NHS, keytruda

NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …

News
merckincweb

Positive five-year Keytruda survival data revealed at ESMO in metastatic, PD-L1+ non-small cell lung cancer

September 22, 2020
Manufacturing and Production, Research and Development ESMO 2020, MSD, keytruda, pharma

MSD took the opportunity at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to unveil new Phase 3 …

News
shutterstock_38078521

New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …

News
shutter

MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations

May 29, 2020
Medical Communications, Research and Development Lenvima, keytruda, pharma

MSD has pulled back the curtain on new data from two trials of its anti-PD-1 immunotherapy Keytruda (pemvbrolizmuab) in combination …

News
merckwindow_web

MSD’s Keytruda hits Phase 3 main goal in first-line colorectal cancer sub-population

April 3, 2020
Medical Communications, Research and Development MSD, colorectal cancer, keytruda, pharma

MSD has lifted the veil on new Phase 3 for its blockbuster immunotherapy Keytruda, showing that the anti-PD-1 therapy met …

News
merck-keytruda

Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund

March 12, 2020
Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …

News
merckincweb

New Keytruda dosing schedule rejected in six cancers by the FDA

February 20, 2020
Sales and Marketing Cancer, FDA, MSD, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda has been stopped in its tracks by the FDA after the US regulator rejected its application …

News

Latest content

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024